Gleevec All Financial Data in US $ (mln)

Word Search (Top 10 - by date)

BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment
BioLineRx (April 10, 2014)
Seragon Pharmaceuticals Appoints Debasish Roychowdhury, M.D. to its Clinical and Scientific Advisory Board and as Acting Chief Medical Officer
Seragon Pharmaceuticals (April 03, 2014)
Stemline Therapeutics Announces Presentation of SL-501 Preclinical Efficacy Data in TKI-Resistant CML at the Annual Meeting of the American Association of Cancer Research (AACR)
Stemline Therapeutics (April 01, 2014)
Ignyta Appoints Sara Zaknoen, M.D., as Chief Medical Officer
Ignyta (February 19, 2014)
BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia
BioLineRx (February 12, 2014)
Sideris Pharmaceuticals Appoints Gregory I. Berk, M.D., as President and Chief Medical Officer
Sideris Pharmaceuticals (January 07, 2014)
Data Highlights BGB324 as a Potential Novel Treatment Option for Drug Resistant Chronic Myeloid Leukemia
BerGenBio (December 17, 2013)
Hybrigenics’ Inecalcitol Synergizes with Imatinib to Inhibit the Growth of Chronic Myeloid Leukemia Stem Cells in Vitro
Hybrigenics (December 09, 2013)
New five-year data support superiority of Novartis drug Tasigna® over Gleevec® in newly diagnosed Ph+ CML patients
Novartis (December 08, 2013)
Novartis to highlight long-term data, innovative pipeline for patients with hematologic diseases and breast cancer at ASH and SABCS
Novartis (December 04, 2013)

Displaying 10 out of a possible 562 unique stories.
Results Sorted By date
Display All Stories

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.

Product Name Information

Product: Gleevec
Generic Name:   imatinib mesylate
Therapeutic Subcategory:     Other cytostatics

Product Sales Summary 2009/10

Annual Sales WW - Sales Growth per Year (%)
Rank1 Generic Name Therapeutic Subcategory 2010
Gleevec2 4,265

Clinical Trial Coverage: No. of Trials involving Product

Trial Count
Gleevec3 594


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download analysis into Excel
  • Search 2 yrs of company press releases

Research Codes Synonyms

Product:4 Gleevec

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now